All of Vantage's Covid-19 stories in one place: share price reactions, clinical trial delays, cost estimates, and more. This page will be updated as our coverage…
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
As Cepi asks for $2bn to fund development of a vaccine against coronavirus and Moderna moves into the clinic, Vantage takes a look at previous pandemic development costs.
Money will of course be no object when it comes to funding development of treatments for Covid-19, but how much exactly are we talking?
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?